Article ID Journal Published Year Pages File Type
3847690 American Journal of Kidney Diseases 2014 13 Pages PDF
Abstract
Use of end points based on 30% or 40% eGFR declines is an appropriate strategy to reduce sample size in certain situations. However, risk for type 1 error is increased in the presence of acute effects, particularly for 30% eGFR declines. The decision to use these end points should be made after thorough evaluation of their expected performance under the conditions of specific clinical trials.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Authors
, , , , , , , , , ,